Literature DB >> 30121316

Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.

Masato Kiyoshi1, Hiroko Shibata2, Akira Harazono1, Tetsuo Torisu3, Takahiro Maruno4, Michiko Akimaru5, Yuuka Asano6, Mai Hirokawa7, Keisuke Ikemoto7, Yukari Itakura8, Takafumi Iwura9, Aya Kikitsu10, Takashi Kumagai11, Naoki Mori7, Hiroaki Murase6, Hirotaka Nishimura12, Atsushi Oda13, Taiichiro Ogawa14, Takuma Ojima5, Shinji Okabe6, Shuntaro Saito5, Satoshi Saitoh15, Hiroyuki Suetomo9, Kazuhiro Takegami14, Momoko Takeuchi10, Hidehito Yasukawa6, Susumu Uchiyama16, Akiko Ishii-Watabe1.   

Abstract

The evaluation of subvisible particles, including protein aggregates, in therapeutic protein products has been of great interest for both pharmaceutical manufacturers and regulatory agencies. To date, the flow imaging (FI) method has emerged as a powerful tool instead of light obscuration (LO) due to the fact that (1) protein aggregates contain highly transparent particles and thereby escape detection by LO and (2) FI provides detailed morphological characteristics of subvisible particles. However, the FI method has not yet been standardized nor listed in any compendium. In an attempt to assess the applicability of the standardization of the FI method, we conducted a collaborative study using FI and LO instruments in a Japanese biopharmaceutical consortium. Three types of subvisible particle preparations were shared across 12 laboratories and analyzed for their sizes and counts. The results were compared between the methods (FI and LO), inter-laboratories, and inter-instruments (Micro Flow Imaging and FlowCam). We clarified the marked difference between the detectability of FI and LO when counting highly transparent protein aggregates in the preparations. Although FlowCam provided a relatively higher number of particles compared with MFI, consistent results were obtained using the instrument from the same manufacturer in all 3 samples.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords:  image analysis; microparticle(s); particle size; protein aggregation; standards

Mesh:

Substances:

Year:  2018        PMID: 30121316     DOI: 10.1016/j.xphs.2018.08.006

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life Cycle.

Authors:  Roman Mathaes; Linda Narhi; Andrea Hawe; Anja Matter; Karoline Bechtold-Peters; Sophia Kenrick; Sambit Kar; Olga Laskina; John Carpenter; Richard Cavicchi; Ellen Koepf; E Neil Lewis; Rukman De Silva; Dean Ripple
Journal:  AAPS J       Date:  2019-10-30       Impact factor: 4.009

2.  Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.

Authors:  Zhen-Yi Jing; Guo-Li Huo; Min-Fei Sun; Bin-Bin Shen; Wei-Jie Fang
Journal:  Pharm Res       Date:  2022-01-26       Impact factor: 4.200

3.  Flow imaging microscopy as a novel tool for high-throughput evaluation of elastin-like polymer coacervates.

Authors:  Laura Marvin; Wynter Paiva; Nicole Gill; Marissa A Morales; Jeffrey Mark Halpern; James Vesenka; Eva Rose M Balog
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.